http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full
See full text for abbreviations and context.
Given their rapid emergence and lack of predictability,
emerging pathogens challenge the current testing paradigm...
An alternate way to manage the continuous threat of
emerging infectious agents is the use of PI technologies
to proactively protect the blood supply and mitigate the
risk of TTIDs. PI = Pathogen Inactivation
The findings of this study are of particular importance
after the US FDA recommended in August 2016 to
1) test all donations collected with a licensed or investigational
individual donor NAT for ZIKV under an investigational
new drug application, 2) to implement pathogen reduction
technology for PLTs and plasma using FDA-approved
devices, or 3) to implement pathogen reduction technology
for whole blood or RBCs if an FDA-approved or
investigational device becomes available.
The amotosalen/UVA systems for plasma and PLTs were
approved by FDA in 2014 and were commercially available
when ZIKV emerged in the Americas and the INTERCEPT
Blood System for PLTs was implemented at the time of the
ZIKV crisis in Puerto Rico in February 2016 to safeguard
and maintain the availability of the blood supply on the island.[60]
The results of this study complement previous results[65]
and show that ZIKV can be inactivated in all blood components
(Table 3) using amotosalen/UVA for PLTs and plasma[41]
and S-303 and GSH for RBCs. The availability of broad spectrum
PI technologies for all blood components enables a new paradigm
for blood safety that can be used to maintain the ongoing
availability and safety of blood products in time of epidemics
with newly emerged and potentially susceptible pathogens.
A great reason to buy while the price is at the $4 mark.... but not for long!!
Recent CERS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 09:05:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 08:14:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:28:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:35:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:41:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:07:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 08:09:19 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/01/2024 09:31:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:54:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:02:08 PM
- Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range • Business Wire • 08/01/2024 08:00:00 PM
- Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024 • Business Wire • 07/18/2024 12:30:00 PM
- Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors • Business Wire • 07/02/2024 08:00:00 PM
- Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion • Business Wire • 06/21/2024 12:30:00 PM
- Cerus Corporation Celebrates World Blood Donor Day 2024 • Business Wire • 06/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:03:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:02:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:00:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:59:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:58:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:57:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:54:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:52:59 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:01:50 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM